跳至主要内容
临床试验/IRCT2013081914407N1
IRCT2013081914407N1已完成未知

The effect of combined therapy with erythropoetin and methylprednisolone in severe relapse of Multiple Sclerosis patients

Tehran university of medical science research assistance0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 45 years(—)
性别
All

入选标准

  • definite diagnosis of MS; age between 18 and 45 years old and motor force 3/5 or less at presentation.
  • Exclusion criteria: pregnancy; brestfeeding; history of diabetes mellitus, hypertension, hyperlipidmia, heavy cigarette smoking, ischemic heart disease, myocardial infarction, cerebovasculaar accident; family history of ischemic heart disease and /or cerebrovascular accident before 45 years; presence of thrombocytosis; presence of polycytemia(hematocrite above 50% in males and above 45% in females); presence of CRF(chronic renal failure); history of any vasculitis or collagen vascular disease; use of contraceptive medication; use of iron substitution; past history of thromboembololic events and any kind of malignancy(treated or untreated).

排除标准

  • 未提供

研究者

发起方
Tehran university of medical science research assistance

相似试验

The effect of erythropoetin on Multiple Sclerosis | 临床试验